A distinct topology of BTN3A IgV and B30.2 domains controlled by juxtamembrane regions favors optimal human γδ T cell phosphoantigen sensing

Butyrophilin (BTN)–3A and BTN2A1 molecules control the activation of human Vγ9Vδ2 T cells during T cell receptor (TCR)-mediated sensing of phosphoantigens (PAg) derived from microbes and tumors. However, the molecular rules governing PAg sensing remain largely unknown. Here, we establish three mechanistic principles of PAg-mediated γδ T cell activation. First, in humans, following PAg binding to the intracellular BTN3A1-B30.2 domain, Vγ9Vδ2 TCR triggering involves the extracellular V-domain of BTN3A2/BTN3A3. Moreover, the localization of both protein domains on different chains of the BTN3A homo-or heteromers is essential for efficient PAg-mediated activation. Second, the formation of BTN3A homo-or heteromers, which differ in intracellular trafficking and conformation, is controlled by molecular interactions between the juxtamembrane regions of the BTN3A chains. Finally, the ability of PAg not simply to bind BTN3A-B30.2, but to promote its subsequent interaction with the BTN2A1-B30.2 domain, is essential for T-cell activation. Defining these determinants of cooperation and the division of labor in BTN proteins improves our understanding of PAg sensing and elucidates a mode of action that may apply to other BTN family members.

Research involving human participants, their data, or biological material Policy information about studies with human participants or human data.See also policy information about sex, gender (identity/presentation), and sexual orientation and race, ethnicity and racism.Note that full information on the approval of the study protocol must also be provided in the manuscript.

Reporting on sex and gender
Field-specific reporting

Life sciences study design
All studies must disclose on these points even when the disclosure is negative.

Sample size
Sample sizes were not predetermined and it was based on the availability.For confocal imaging, FRAP and FRET n=>10 samples were analysed for each cell type.

Data deposition
Confirm that both raw and final processed data have been deposited in a public database such as GEO.
Confirm that you have deposited or provided access to graph files (e.g.BED files) for the called peaks.
Data access links (For "Initial submission" or "Revised version" documents, provide reviewer access links.For your "Final submission" document, May remain private before publication.provide a link to the deposited data.

Files in database submission
Genome browser session (e.g.I

Methodology
Replicates Sequencing depth

Peak calling parameters
Provide a list of all files available in the database submission.
Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review.Write "no longer applicable" for "Final submission" documents.
Describe the experimental replicates, specifying number, type and replicate agreement.
Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired-or single-end.L s_ econd levels (e.g.fixed, random or mixed effects; drift or auto-correlation).
[ Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.

Whole brain I__I ROI-based Both
Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.
Describe the type of correction and how it is obtained for multiple comparisons (e.g.FWE, FDR, permutation or Monte Carlo).

Models & analysis
with informed consent according to the University of Wuerzburg institutional review board (Gz.20220927 01) Please select the one below that is the best fit for your research.If you are not sure, read the appropriate sections before making your selection.
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summarytlat.p Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g.original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.
Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.
Report the measures of dependence used and the model details (e.g.Pearson correlation, partial correlation, mutual information).Graph analysisReport the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject-or group-level, and the global and/or node summaries used (e.g.clustering coefficient, efficiency, etc.).Multivariate modeling and predictive analysis Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.